|
Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; MSD; Novartis; Roche; Sanofi; Takeda |
|
|
Honoraria - Amgen; Celgene; Janssen-Cilag; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen-Cilag; Takeda |
|
|
|
Consulting or Advisory Role - Prothena |
Travel, Accommodations, Expenses - Janssen |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda |
|
|
Honoraria - Amgen; Genesis Pharma; Janssen Oncology; Takeda |
Consulting or Advisory Role - Amgen; Janssen Oncology; Takeda |
Research Funding - Amgen (Inst); Janssen Oncology (Inst) |
Travel, Accommodations, Expenses - Genesis Pharma; Janssen Oncology |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Takeda |
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Takeda |
|
Carlos Fernández de Larrea Rodríguez |
Honoraria - Amgen; Celgene; Janssen; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen |
Research Funding - Amgen; Celgene; Janssen; Takeda |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen; Takeda |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen Oncology; Millennium |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen Oncology; Takeda |
Research Funding - Celgene; Janssen Oncology |
|
|
Travel, Accommodations, Expenses - Prothena |
|
|
No Relationships to Disclose |
|
|
Honoraria - Art tempi; Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen-Cilag; Novartis |
Consulting or Advisory Role - Adaptive Biotechnologies (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen-Cilag (Inst); Sanofi (Inst); Takeda (Inst) |
Speakers' Bureau - Art tempi; Bristol-Myers Squibb; Celgene; Chugai Pharma Europe; Janssen; Novartis |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma Europe (Inst); Janssen (Inst); Mundipharma (Inst); Novartis (Inst); Sanofi (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Novartis; Sanofi; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Janssen Research & Development |
|
|
|
Stock and Other Ownership Interests - Janssen |
Travel, Accommodations, Expenses - Janssen |
Other Relationship - Janssen |
|
|
Employment - Janssen Research & Development |
Research Funding - Janssen Research & Development |
|
|
Employment - Cornerstone Research Group |
Stock and Other Ownership Interests - Cornerstone Research Group |
Other Relationship - Patented Medicine Prices Review Board |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Celgene; Janssen; Takeda |
|
|
|
Consulting or Advisory Role - Abbvie (Inst); Abbvie (Inst); Adaptive Biotechnologies; Amgen (Inst); Celgene (Inst); Genecentrix; Genentech/Roche (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Merck (Inst); Oncopeptides; Takeda (Inst) |
Research Funding - Abbvie (Inst); Celgene (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst) |